Its apparent they can't get anything going after their third failure within a year. So maybe its time for BIO TIME to step in and rescue this thing? Afterall the CEO of BIO TIME, Dr. Michael West, was the original founder of Geron.
What does GERN have that would attract a meaningful buyout. No products, a Dec 9 trial results, nothing else in the pipeline.
BioTime has no money. That also concerns me about the hESC platform. GERN had $25 Million from CIRM and ~$150 Million in the bank when they dropped hESC.
BioTime is proposing around $10 Million in funding to support the platform. Ridiculous.
These three biotech's are in a financial mess, ACT, BTX, and GERON. Maybe they need to consolidate?